Latest Period
Q1 2026
Security Snapshot
Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB) Institutional Ownership
CUSIP: 034569103
13F Institutional Holders and Ownership History from Q2 2021 to Q1 2026
Institutions Reporting
0
Shares (Excl. Options)
0
Price
$0.87
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- ANEB on OTC
- Shares outstanding
- 41,587,315
- Price per share
- $0.87
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 0
- Total reported value
- $0
- Share change
- -6,305,565
- Value change
- -$6,368,735
- Number of holders
- 0
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- ANEB - Anebulo Pharmaceuticals, Inc. - Common Stock is tracked under CUSIP 034569103.
- 0 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 16 to 0 between Q4 2025 and Q1 2026.
- Reported value moved from $6,808,914 to $0.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 0 institutions filings for Q1 2026.
Security key
034569103
Latest holder period
Q1 2026
13F holders
0
13D/G owners
3
CIK / CUSIP context first
Open Q1 2026 holders
ANEB full holder history
Anebulo Pharmaceuticals, Inc. SEC filings
Anebulo Pharmaceuticals, Inc. company facts
Anebulo Pharmaceuticals, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 034569103:
Significant Owners of Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| English Aron R. | 51% | 0% | $25,877,258 | 21,929,880 | 0% | Aron R. English | 24 Feb 2025 | |
| Nantahala Capital Management, LLC | 8.5% | -1.1% | $3,582,872 | 3,547,398 | 0% | Nantahala Capital Management, LLC | 31 Dec 2025 | |
| MANGROVE PARTNERS IM, LLC | 6.2% | $2,979,797 | 2,525,252 | Mangrove Partners IM, LLC | 31 Dec 2024 |
As of 31 Mar 2026, 0 institutional investors reported holding 0 shares of Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB). This represents 0% of the company’s total 41,587,315 outstanding shares.
Institutional Holders of Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 0 | $0 | -$6,368,735 | $0.87 | 0 |
| 2025 Q4 | 6,741,386 | $6,808,914 | -$68,403 | $1.01 | 16 |
| 2025 Q3 | 22,219,763 | $55,549,711 | -$356,433 | $2.50 | 20 |
| 2025 Q2 | 22,591,946 | $32,532,431 | -$34,513 | $1.44 | 18 |
| 2025 Q1 | 22,618,242 | $29,403,638 | +$39,506 | $1.30 | 18 |
| 2024 Q4 | 22,570,347 | $37,311,560 | +$24,974,043 | $1.68 | 15 |
| 2024 Q3 | 7,343,734 | $14,173,448 | +$69,135 | $1.93 | 13 |
| 2024 Q2 | 7,307,778 | $19,950,292 | +$326 | $2.73 | 12 |
| 2024 Q1 | 7,306,365 | $20,969,328 | +$85,916 | $2.87 | 14 |
| 2023 Q4 | 7,278,993 | $17,615,165 | +$183,945 | $2.42 | 13 |
| 2023 Q3 | 7,050,491 | $21,560,562 | +$51,779 | $3.06 | 11 |
| 2023 Q2 | 7,031,883 | $16,498,373 | +$460,020 | $2.35 | 11 |
| 2023 Q1 | 6,836,130 | $19,834,339 | -$508,787 | $2.90 | 9 |
| 2022 Q4 | 7,046,307 | $17,074,708 | -$15,992 | $2.42 | 12 |
| 2022 Q3 | 6,842,912 | $19,161,000 | +$6,062,684 | $2.80 | 10 |
| 2022 Q2 | 4,677,847 | $24,324,000 | +$2,192,344 | $5.20 | 8 |
| 2022 Q1 | 4,190,412 | $29,539,000 | -$21,602 | $7.02 | 8 |
| 2021 Q4 | 4,193,307 | $25,818,000 | +$61,833 | $6.21 | 8 |
| 2021 Q3 | 4,183,214 | $27,472,000 | -$109,295 | $6.58 | 7 |
| 2021 Q2 | 4,199,813 | $28,670,000 | +$28,670,000 | $6.85 | 8 |